Back to results
US 2023/0271971 A1Published application
Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
AssigneeBlueprint Medicines Corporation
InventorsJoshua D. Waetzig, Gordon Wilkie
Life of this patent
Estimating the term…
Abstract
Crystalline Forms of Compound (I): pharmaceutically acceptable salts thereof and solvates of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions associated with oncogenic KIT and PDGFRA alterations using the same, and methods for making Compound (I) and crystalline forms thereof are also disclosed.
Claims19
Crystalline Form A of Compound (I):
- characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from 11.5 ± 0.2, 15.4 ± 0.2, 16.7 ± 0.2, 20.0 ± 0.2, and 21.6 ± 0.2.
Dependencies are inferred from the claim text.